康龙绍兴顺利通过美国FDA现场检查,商业化生产质量体系与国际接轨继2025年4月宁波 原料药 生产车间通过美国FDA现场检查后,近日子公司康龙绍兴原料药商业化生产基地首次通过美国FDA新药批准前检查,标志着公司质量体系已与国际接轨,具备持续为美国乃至全球市场提供商业化 创新药 原料药资质,助力板块由研发向商业化生产推进。2025H1公司实现营业收入64.41亿元,同比增长14.9%;随着全球 ...
Source Link康龙绍兴顺利通过美国FDA现场检查,商业化生产质量体系与国际接轨继2025年4月宁波 原料药 生产车间通过美国FDA现场检查后,近日子公司康龙绍兴原料药商业化生产基地首次通过美国FDA新药批准前检查,标志着公司质量体系已与国际接轨,具备持续为美国乃至全球市场提供商业化 创新药 原料药资质,助力板块由研发向商业化生产推进。2025H1公司实现营业收入64.41亿元,同比增长14.9%;随着全球 ...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.